Orchid Pharma shares have delivered impressive returns with a 34.39% gain over the past year, reaching ₹959.8 on NSE and ₹960 on BSE as of June 15, 2026. The stock has traded between a 52-week high of ₹970 and a low of ₹480, with the company maintaining a market capitalization of ₹4,651.45 crore. The pharmaceutical company's strong performance comes as it advances negotiations for its novel antibiotic enmetazobactam in the US market, with management expecting the licensing deal to be finalized in the coming quarter.
Orchid Pharma Ltd is in advanced discussions to out-license its novel antibiotic enmetazobactam in the United States, as the Chennai-based drugmaker seeks a commercial breakthrough in the world's largest pharmaceutical market. According to reports from Moneycontrol, talks with potential partners are at an advanced stage, with a deal likely to be finalised in the near term. "We hope the discussions will be closed in this quarter, coming quarter," whole-time director Mridul Dhanuka said in a recent earnings call. Once an agreement is signed, the product would see a quick launch, as regulatory approval is already in place.
Enmetazobactam, when combined with cefepime and marketed as Exblifep, is used to treat serious bacterial infections, including complicated urinary tract and kidney infections. As reported by Moneycontrol, the therapy secured US regulatory approval in February 2024, a rare instance of an India-origin novel drug clearing a stringent Western regulator. The drug targets resistant bacterial infections, including carbapenem-resistant strains, making it a critical addition to the limited arsenal of next-generation antibiotics.
Beyond the US, Orchid is negotiating licensing agreements across Japan, Russia, Latin America and Southeast Asia, with discussions at different stages — from term sheets to definitive agreements. According to Moneycontrol, "Lots of them are in advanced discussion, and we hope to sign a lot of deals this year," Dhanuka said. The company expects at least half of these partnerships to be signed over the next few quarters, reflecting strong global interest in the molecule. In India, Orchid has partnered with Cipla to distribute the drug.
Orchid continues to peg enmetazobactam-cefepime's lifetime global sales potential at $1 billion to $2 billion, depending on adoption rates across hospital systems and insurance coverage. As reported by Moneycontrol, the drug targets resistant bacterial infections, including carbapenem-resistant strains, making it a critical addition to the limited arsenal of next-generation antibiotics. Management said feedback from global opinion leaders has been consistently positive, with pricing and reimbursement emerging as the key determinants of uptake.
Orchid Pharma reported mixed financial results for Q2 FY 2025-26, with consolidated revenues increasing 10.8% quarter-on-quarter but declining 11.3% year-on-year. The company's net profit decreased 138.4% QoQ and 121.0% YoY, while earnings per share declined to ₹1.13 during the quarter. Despite the challenging financial performance, the company's stock has maintained strong momentum, reflecting investor confidence in its licensing prospects and antibiotic portfolio.
